New west nile vaccine trial aims to stop Mosquito-Borne threat
NCT ID NCT06745921
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 32 times
Summary
This early-stage trial tests a new vaccine called HydroVax-001B WNV to see if it is safe and triggers an immune response against West Nile virus, which is spread by mosquitoes. The study involves 30 healthy adults aged 18 to 49 who will receive either the vaccine or a placebo. Participants get three shots over six months, and researchers will monitor for side effects and measure antibody levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WEST NILE VIRAL INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Saint Louis University Center for Vaccine Development
St Louis, Missouri, 63104-1015, United States
Conditions
Explore the condition pages connected to this study.